You searched for "PCa"
Preoperative risk stratification of high-risk prostate cancer patients
High-risk prostate cancer (HRPCa) is associated with a significant risk of recurrence after radical treatment. While several classification systems exist, the D’Amico criteria – based on clinical T stage ≥T2c, prostate specific antigen (PSA) ≥20 ng/mL, or Gleason score (GS)...Rishi Sunak joins Prostate Cancer Research as an ambassador
Rishi Sunak with three prostate cancer patients at the Oxford BioDynamics labs. (From left to right: Dafydd Charles, Briane Milne, Rishi Sunak, Alfred Samuels). Former UK Prime Minister Rishi Sunak has joined Prostate Cancer Research as an ambassador, to champion...Supporting Patients Receiving Hormone Therapy: Introducing LiveWell
Androgen deprivation therapy (ADT) is a cornerstone of prostate cancer treatment, yet up to 30% of men experience significant long-term side effects affecting physical, metabolic, and psychological wellbeing. While there is strong evidence supporting exercise, lifestyle, and psychosocial interventions, access...Updated guide on integrated paediatric continence services to significantly improve children’s lives and save NHS cost
The Paediatric Continence Forum has recently launched its updated Guide on how to commission and run integrated, nurse-led, community-based paediatric bladder and bowel (continence) services. These are clinically effective, improve the lives of children and their families and generate significant...Prostate cancer
Case 1 What is prostate specific antigen (PSA) and what is its function? According to the ERSPC Trial (at 13 years), what was the number needed to screen and diagnosed to prevent one prostate cancer death and what was the...UTI Diagnostics: A Practitioner’s Guide to the Testing Landscape
Join Bladder Health UK for an independent CPD-style webinar exploring the evolving diagnostic landscape for urinary tract infections. With expert insights from Gabrielle Gleeson‑Solomon and Nick Parkinson PhD (Tota), this session will help clinicians navigate the complexities of UTI testing,...Join Prostate Cancer Research Free Webinar for Healthcare Professionals
Managing Sexual Side Effects After Prostate Cancer: A Patient & Therapist Perspective Date: 20 January 2026 — 6.00pm (London)Register: https://zoom.us/webinar/register/WN_CstOkvaUSNSg_xlFI1Z27w Why attend?Sexual side effects remain one of the most challenging and under-discussed consequences of prostate cancer treatment. This focused webinar...
Malignant upper urinary tract obstruction: emergency presentations and long-term outcomes
Malignant upper urinary tract obstruction (MUUTO) is a frequent emergency urological referral, often necessitating kidney drainage to preserve renal function. However, many patients have advanced cancer with limited life expectancy, raising questions about intervention benefits. While percutaneous nephrostomy (PCN) or...
Performance of non-invasive tests in diagnosing BOO in men with LUTS
A large proportion of urology involves the treatment of bladder outflow obstruction (BOO) in men. Yet BOO in men is very difficult to accurately quantify with the only regular non-invasive test being uroflowmetry. Pressure flow urodynamics may be considered the...Demanding cases or nightmares in uro-oncology? Sep/Oct 2021
Active surveillance for prostate cancer: missing the boat Case In 2005 a 43-year-old man of Afro-Caribbean ethnicity was referred to our centre for investigation of suspected prostate cancer. Digital rectal exam revealed a firm right lobe, PSA of 2.3ng/ml, prostate...
ASAP: is a repeat biopsy necessary?
This study examined the validity of current US and European guidelines on the management of patients diagnosed with atypical small acinar proliferation (ASAP). Current guidance states that these patients should undergo repeat biopsy within three to six months due to...
